Blocking Substance P's Receptor Reduces Inflammation in Human Spinal Disc Cells

In vitro laboratory study using human intervertebral disc cells (both annulus fibrosus and nucleus pulposus). Cells were expanded in monolayer culture, then suspended in alginate beads to maintain a 3D environment. Cells were treated with the NK1R antagonist L-760735 at different concentrations, then stimulated with Substance P. Gene expression of inflammatory cytokines (IL-1β, IL-6, IL-8) was measured by quantitative RT-PCR. Signaling pathway activation was assessed by Western blot for phosphorylated p38-MAPK, ERK1/2, and NF-κB p65. Specific pathway inhibitors confirmed the signaling mechanisms.

Chronic back pain from disc degeneration affects hundreds of millions of people worldwide, and current treatments (painkillers, steroids, surgery) are often inadequate. This study identifies a specific molecular target — the NK1 receptor — that could be blocked to reduce inflammation directly in disc tissue. Unlike broad anti-inflammatory drugs, targeting Substance P signaling could address the root cause of disc inflammation without widespread side effects.

Substance P has long been known as a pain peptide, but its role in driving inflammation within spinal disc tissue has only recently been explored. This study fills a critical gap by mapping the exact signaling pathways in human disc cells and showing they can be pharmacologically blocked. NK1R antagonists already exist as drugs (some were developed for nausea and depression) — this research suggests they could potentially be repurposed or reformulated for treating discogenic back pain, a condition affecting a significant portion of the global population.

This is an in vitro study using cultured human disc cells in alginate beads, which doesn't fully replicate the complex environment of a living disc. The study tested only one NK1R antagonist (L-760735). Cell culture conditions may alter receptor expression and signaling compared to in vivo. The clinical translation — whether blocking NK1R in disc tissue would reduce pain in patients — remains untested. The source and condition of the human disc cells (healthy vs. degenerated) could affect results.